Literature DB >> 20362865

Iris-fixated phakic intraocular lens implantation for correction of high myopia in microspherophakia.

Majid Moshirfar1, Jay J Meyer, Joshua A Schliesser, Ladan Espandar, Joann C Chang.   

Abstract

We report the refractive correction of high myopia in a 23-year-old patient with idiopathic microspherophakia using iris-fixated phakic intraocular lenses (pIOLs) (Verisyse/Artisan). Four years after bilateral implantation, the uncorrected distance visual acuity was 20/25 with a correction of 20/20(-1) in both eyes. No intraoperative or postoperative complications occurred. Iris-fixated pIOLs are not recommended for every patient with microspherophakia. However, this procedure may be an option in microspherophakic patients with appropriate anterior chamber depth and no history of lens dislocation who are likely to comply with annual eye examinations. Follow-up should include monitoring the endothelial cell count and biomicroscopy for adequate space between the pIOL, the natural crystalline lens, and the corneal endothelium. Scheimpflug photography can be a valuable tool in such cases. Copyright (c) 2010 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20362865     DOI: 10.1016/j.jcrs.2009.08.043

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  3 in total

1.  Factors Related to Visual Outcomes after Lens Surgery in Isolated Microspherophakia.

Authors:  Jialei Zheng; Lina Cheng; Zexu Chen; Tianhui Chen; Yongxiang Jiang
Journal:  J Ophthalmol       Date:  2022-06-15       Impact factor: 1.974

2.  Incidence rate and occurrence of visually significant cataract formation and corneal decompensation after implantation of Verisyse/Artisan phakic intraocular lens.

Authors:  Majid Moshirfar; Lauren M Imbornoni; Erik M Ostler; Valliammai Muthappan
Journal:  Clin Ophthalmol       Date:  2014-04-08

3.  Scleral-fixated intraocular lens implantation in microspherophakia.

Authors:  Sujata Subbiah; Philip A Thomas; C A Nelson Jesudasan
Journal:  Indian J Ophthalmol       Date:  2014-05       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.